Novel research translates to clinical cases of schizophrenic and cocaine psychosis

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 4, 2007, Pages 475-485

  Nunes, João V ^a   Broderick, Patricia A ^a,b  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical antipsychotic; Cocaine psychosis; Psychopharmacotherapy; Risperidone; Schizophrenia; Typical antipsychotic

Indexed keywords

AMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; COCAINE; DIPHENHYDRAMINE; DIURETIC AGENT; DOPAMINE; HALOPERIDOL; LONG ACTING DRUG; LORAZEPAM; NEUROLEPTIC AGENT; PEROSPIRONE; RISPERIDONE; SEROTONIN;

BRONCHITIS; CLINICAL TRIAL; COCAINE DEPENDENCE; DRUG MECHANISM; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; HEALTH CARE COST; HUMAN; LIFE STRESS; NONHUMAN; PRENATAL EXPOSURE; PREVALENCE; PSYCHOLOGICAL ASPECT; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; RHINITIS; RISK FACTOR; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL ASPECT; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; WITHDRAWAL SYNDROME;

EID: 35648956723     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Abi-Dargham A, Gil R, Krystal J, et al. 1998. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiat, 155:761-3.
2. Angelopoulos EK, Markianos M, Daskalopoulou EG, et al. 2002. Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia. Psychiatry Res, 110:9-17.
3. Andreasen NC. 1982. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psych, 39:784-8.
4. Andreasen NC. 1987. The diagnosis of schizophrenia. Schizophr Bull, 13:9-22.
5. Bersani G, Orlandi V, Kotzalidis G, et al. 2002. Cannabis and Schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci, 252:86-92.
6. Bleuler E. 1911. "Dementia Praecox or Group of Schizophrenias". Germany.
7. Blum K, Trachtenberg MC, Kowzlowski GP. 1989. Cocaine therapy: the "reward. cascade" link. Prof Counselor, Jan/Feb:327-35.
8. Bradberry CW, Nobiletti JB, Elsworth JD, et al. 1993. Cocaine and cocaethylene: microdialysis comparison of brain drug levels and effects on dopamine and serotonin. J Neurochem, 60:1429-35.
9. Bradberry CW, Roth RH. 1989. Cocaine increases extracellular dopamine in rat nucleus accumbens and ventral tegmental area as shown by in vivo microdialysis. Neurosci Lett, 103:97-102.
10. Brady KT, Lydiard RB, Malcolm R, et al. 1991. Cocaine-induced psychosis. J Clin Psychiatry, 52(12):509-12.
11. Broderick PA. 1991a. Cocaine: on-line analysis of an accumbens amine neural basis for psychomotor behavior. Pharmacol Biochem Behav, 40:959-68.
12. Broderick PA. 1991b. In vivo voltammetric studies on release mechanisms for cocaine with gamma-butyrolactone. Pharmacol Biochem Behav, 40:969-75.
13. Broderick PA. 1992a. Cocaine's localized effects on synaptic serotonin and dopamine in ventral tegmentum in a reinforcement paradigm. Pharmacol Biochem Behav, 42:889-98.
14. Broderick PA. 1992b. Distinguishing effects of cocaine I.V. and S.C. on mesoaccumbens dopamine and serotonin release with chloral hydrate anesthesia. Pharmacol Biochem Behav, 43(3):929-37.
15. Broderick PA. 2002. Microsensors detect cocaine neuroadaption: serotonin release within basal ganglia is not rhythmic with movement. In: Massaro EJ, Schardien JL, Broderick PA, et al. (eds). Handbook of Neurotoxicity. Totowa, NJ: Humana Pr, 2:323-67.
16. Broderick, PA, Hope O, 2006. Monoamine and motor responses are co-deficient in the Fawn-Hooded depressed animal. Prog Neuropsychopharmacol & Biol Psychiat, 30:887-98.
17. Broderick PA, Kornak EP, Eng F, et al. 1993. Real time detection of acute (IP) cocaine-enhanced dopamine and serotonin release in ventrolateral nucleus accumbens of the behaving Norway rat. Pharmacol Biochem Behav, 46(3):715-22.
18. Broderick PA, Phelix CF. 1997. I. Serotonin (5-HT) within dopamine reward circuits signals open-field behavior. II. Basis for 5-HT-dopamine interaction in cocaine dysfunctional behavior. Neurosci Behav Rev, 21(3):227-60.
19. Broderick PA, Rahni DN, Zhou Y. 2003. Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior. Prog Neuropsychopharmacol & Biol Psychiat, 27(6):1037-54.
20. Broderick PA, Piercey MF. 1998. Clozapine, haloperidol, and the D4 antagonist PNU-101387G: in vivo effects on mesocortical, mesolimbic, nd nigrostriatal dopamine and serotonin release. J Neural Transm, 105(6-7):749-767.
21. Buckley PF. 1998. Substance abuse in schizophrenia: A review. J Clin Psychiat, 3(Suppl):S26-30.
22. Carlsson A, Carlsson ML. 2006. Dopaminergic deficient hypothesis of schizophrenia: the path to discovery. Dialogues Clin Neurosci, 8(1):137-42.
23. Carpenter WT, Jr. 1998. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry, 145(5):578-83.
24. Carroll FI, Gray JL, Abraham P, et al. 1993. 3-Aryl-2-(3′- substituted-1′,2′,4′-oxadiazol-5′-yl) tropane analogues of cocaine: affinities at the cocaine binding site at the dopamine, serotonin and norepinephrine transporters. J Chem, 36:2886-90.
25. Church WH, Justice JB, Jr, Byrd LD. 1987. Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine, and benztropine. Eur J Pharmacol, 139(3):325-48.
26. Cubells JF, Feinn R, Pearson D, et al. 2005. Rating the severity and character of transient cocaine-induced delusions and hallucinations with a new instrument, the Scale for Assessment of Positive Symptoms for Cocaine-Induced Psychosis (SAPS-CIP). Drug Alcohol Depend, 80(1):23-33.
27. Conley RR, Mahmoud R, 2001. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry, 158(5):765-774.
28. Cools AR, van Rossum JM. 1970. Caudal dopamine and stereotype behaviour of cats. Arch Int Pharmacodyn Ther, 187(1): 163-73.
29. Costall B, Naylor RJ, 1973. The role of the substantia nigra in the locomotor stimulant action of amphetamine. Br J Pharmacol, 49(1):29-37.
30. Cunningham KA, Lakoski JM. 1988. Electrophysiological affects of cocaine and procaine on dorsal raphe serotonin neurons. Eur J Pharmacol, 148:457-62.
31. De Wit H, Wise RA. 1977. Blockade of cocaine reinforcement in rats with the dopamine receptor blockade pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can J Psychol, 31(4):195-203.
32. Docherty JP, Bossie CA, Lachaux B, et al. 2007. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol, 22:51-5.
33. Einhorn LC, Johansen PA, White FJ. 1988. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. J Neurosci, 8(1):100-112.
34. Evenden JL, Ryan CN. 1998. Behavioral responses to psychomotor stimulant drugs: localization in the central nervous system. Pharmacol Ther, 36(2-3):151-72.
35. Farde L, Wiesel FA, Hallain C, et al. 1988. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry, 45(1):71-6.
36. Filip M, Cunningham KA. 2002. Serotonin 5-HT(2) receptors in nucleus accumbens regulate expression of the hyperlocomotive and discriminative stimulus effects of cocaine. Pharmacol Biochem Behav, 71(4):745-56.
37. Gawin F, Kleber H. 1986. Pharmacologic treatments of cocaine abuse. Psychiatr Clin North Am, 9(3):573-83.
38. Goeders NE, Smith JE. 1983. Cortical dopaminergic involvement in cocaine reinforcement. Science 221(4612):773-75.
39. Grabowski J, Rhoades H, Silverman P, et al. 2000. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial, J Clin Psychopharmacol, 20(3):305-10.
40. Green AI, Tohen MF, Hamer RM, et al. 2004. First episode schizophrenia-related psychosis and substance use disorders: acute response to clozapine and haloperidol. Schizophr Res, 66(2-3):125-35.
41. Green AI, Zimmet SV, Strous RD, et al. 1999. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiat, 6(6):287-96.
42. Hall FS, Li XF, Sora I, et al. 2002. Cocaine mechanisms: enhanced cocaine, fluoxetine, and nisoxetine place preferences following monoamine transporter deletions. Neuroscience, 115(1):153-61.
43. Harris D, Batki SL. 2000. Stimulant psychosis: symptom profile and acute clinical course. Am J Addict, 9(1):28-37.
44. Hietala J, Syvalahti E, Vuorio K, et al. 1995. Presynaptic dopamine function in striatum of neuroleptic-naïve schizophrenic patients. J Lancet, 346:1130-31.
45. Herve D, Pickel VM, Job TH, et al. 1987. Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res, 435:71-83.
46. Huff RM, Adams RN. 1980. Dopamine release in n. accumbens and striatum by clozapine: simultaneous monitoring by in vivo electrochemistry. Neuropharmacology, 19:587-90.
47. Hurd YL, Ungerstedt U. 1989. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol, 166(2):251-60.
48. Ichikawa J, Kuroki T, Dai J, et al. 1998. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol, 351(2):163-71.
49. Ishibashi T, Tagashira R, Nakamura M, et al. 1999. Effects of perospirone, a novel 5-HT2 and D2 receptor antagonist, on Fos protein expression in the rat forebrain. Pharmacol Biochem Behav, 63(4):535-41.
50. Kalivas PW. 1993. Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res Rev, 81(1):75-113.
51. Kalivas PW, Duffy P, 1990. Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. J Neurosci, 10(9):2940-9.
52. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al. 2000. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiat, 48:627-40.
53. Kleber H, Gawin F. 1986. Psychopharmacological trials in cocaine abuse treatment. Am J Drug Alcohol Abuse, 12:235-46.
54. Lysaker P, Bell M, Beam-Goulet J, et al. 1994. Relationship of positive and negative symptoms to cocaine abuse in schizophrenia. J Nerv Ment Dis, 182(2):109-112.
55. Mauri M, Volonteri L, De Gaspari I, et al. 2006. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Prac Epidemol Ment Health, 2:4.
56. Malaspina D, Brown A, Goetz D, et al. 2002. Schizophrenia risks and paternal age: a potential role for de novo mutations in schizophrenia vulnerability genes. CNS Spectr, 7(1):26-9.
57. Meltzer H. 1989. Serotonergic dysfunction in depression. Br J Psychiatry Suppl. (8): 25-31.
58. Meltzer HY. 1992. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull, 18(3):515-42.
59. Meltzer HY, Nash JF. 1991. Effects of antipsychotics on serotonin receptors. Pharmacol Rev, 43(4):587-604.
60. Mendoza R, Miller BL, Mena I. 1992. Emergency room evaluation of cocaine-associated neuropsychiatric disorders. Recent Dev Alcohol, 10:73-87.
61. Miller BL, Mena I, Giombetti R, et al. 1992. Neuropsychiatric effects of cocaine: SPECT measurements. J Addict Dis, 11(4):47-58.
62. Mukherjee J, Christian BT, Narayanan TK, et al. 2001. Evaluation of dopamine D2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology, 25(4):476-88.
63. Naiker DV, Catts SV, Carts VS, et al. 2006. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharm, 540:87-90.
64. Newton TF, Ling W, Kalechstein AD, et al. 2001. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res, 102(3):227-33.
65. Nilsson M, Carlsson A, Markinhuhta KR, et al. 2004. The dopaminergic stabiliser ACR 16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition. Prog Neuropsychpharmacol & Biol Psychiat, 28:677-85.
66. Ohara K. 2007. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Prog Neuropsychopharmacol & Biol Psychiat, 31(2):469-74.
67. Phelix CF, Broderick PA. 1995. Light microscopic immunocytochemical evidence of converging serotonin and dopamine terminals in ventrolateral nucleus accumbens. Brain Res Bull, 37(1):37-40.
68. Pijnenburg AJJ, Honig WMM, van Rossum JM. 1975. Effects of antagonists upon locomotor stimulation induced by injection of dopamine and noradrenaline into the nucleus accumbens of nialamide-pretreated rats. Psychopharmacologia, 41(2):175-80.
69. Ritz MC, Lamb RJ, Goldberg SR, et al. 1987. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science, 237(4819):1219-23.
70. Roberts DC, Koob GF. 1982. Disruption of cocaine self-administration following 6-hydroxydopamine lesions of the ventral tegmental area in rats. Pharmacol Biochem Behav, 17(5):901-4.
71. Rosenheck R, Tekell J, Peters J, et al. 1998. Does participation in psychosocial treatment augment the benefit of clozapine? Arch Gen Psychiat, 55(7):618-25.
72. Rosse RB, Collins JP Jr, Fay-McCarthy M, et al. 1994. Phenomenologic comparison of the idiopathic psychosis of schizophrenia and drug-induced cocaine and phencyclidine psychoses: a retrospective study. Clin Neuropharmacol, 17:359-69.
73. Rung JP, Carlsson A, Markinhuhta KR, et al. 2005. The dopaminergic stabilisers (-)-OSU 6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog Neuropsychopharm & Biol Psychiat A Special Topics Issue (Broderick PA, Glazer WM, eds), 29(5):833-9.
74. Satel SL, Edell WS. 1991. Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry 148(12):1708-11.
75. Schwarz J, Scherer J, Trenkwalder C, et al. 1998. Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy? Psychiatry Res, 83(1):23-8.
76. Serper MR, Chou JC, Allen MH, et al. 1999. Symptomatic overlap of cocaine intoxication and acute schizophrenia at emergency presentation. Schizophr Bull, 25(2):387-94.
77. Smelson DA, Roy A, Roy M. 1997. Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. Can J Psychiatry, 42(9):984.
78. Smelson DA, Losonczy MF, Davis CW, et al. 2002. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. J Can Psychiatry, 47(7):671-5.
79. Smits L, Pedersen C, Mortenson P, et al. 2004. Association between short birth intervals and schizophrenia in the offspring. Schizophr Res, 70(1):49-56.
80. Stahl SM. 2000. Essential Psychopharmacology, 2nd Edition. New York: Cambridge Univ Pr.
81. Sorensen HJ, Mortenson EL, Reinisch JM, et al. 2003. Do hypertension and diuretic treatment in pregnancy increase the risk of schizophrenia in offspring? Am J Psychiatry, 160(3):464-8.
82. Steinbusch HW. 1981. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience, 6(4):557-618.
83. Taylor WA, Staby AE. 1992. Acute treatment of alcohol and cocaine emergencies. Recent Dev Alcohol, 10: 179-91.
84. Tsuang JW, Eckman T, Marder S, et al. 2002. Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychopharmacol, 22(6):629-30.
85. Tueth MJ. 1993. High incidence of psychosis in cocaine intoxication and preventing violence in the ED. Am J Emerg Med, 11(6):676.
86. Van Bockstaele EJ, Cestari DM, Pickel VM. 1994. Synaptic structure and connectivity of serotonin terminals in the ventral tegmental area: potential sites for modulation of mesolimbic dopamine neurons. Brain Res, 647(2):307-22.
87. Van Bockstaele EJ, Pickel VM. 1993. Ultrastructure of serotonin-immuno-reactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamine afferents. J Comp Neurol, 334(4):603-17.
88. Verhoeff NP, Meyer JH, Kecojevic A, et al. 2000. A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia. Psychiatry Res, 99(3):123-35.
89. Wadenberg ML, Sollman A, Vanderspek SC, et al. 2001. Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology, 25(5):633-41.
90. Weiner I, Gaisler I, Schiller D, et al. 2000. The latent inhibition model dissociates between clozapine, haloperidol, and ritanserin. Neuropsychopharmacology, 23(2):151-61.
91. Williams R. 2001. Optimal dosing with risperidone: updated recommendations. Clin Psychiatry, 62:282-9.
92. Wise RA, Bozarth MA. 1987. A psychornotor stimulant theory of addiction. Psychol Rev, 94(4):469-92.
93. Yui K, Goto K, Ikemoto S, et al. 1999. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. J Mol Psychiat, 4(6):512-23.